Evidence map›Paper›PMID 39681616›Full record

ReviewEuropean journal of clinical nutrition2025

Nutraceuticals: a promising, yet unregulated Frontier in Healthcare.

Yoshiyasu Takefuji

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yoshiyasu TakefujiFaculty of Data Science, Musashino University, Tokyo, Japan. takefuji@keio.jp.ORCID http://orcid.org/0000-0002-1826-742X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nutraceuticals, with their potential health benefits, are increasingly being used to manage a variety of health conditions. The global market for nutraceuticals, valued at USD 540 billion in 2022, is projected to reach USD 1025 billion by 2030. This paper delves into the beneficial impacts of emerging nutraceuticals on a spectrum of medical disorders, drawing from credible sources from the National Library of Medicine. We have scrutinized studies on the application of nutraceuticals in treating conditions like sleep disorders, migraines, oxidative stress, mental health issues, pain disorders, obesity, gastrointestinal disorders, and even COVID-19. Our analysis indicates that nutraceuticals hold promise for addressing various health issues. However, this paper also sheds light on the health risks associated with nutraceuticals. Despite their widespread use, the safety and efficacy of nutraceuticals are still uncertain due to the lack of stringent regulations, unlike pharmaceutical drugs. This raises concerns about potential health risks and misleading claims. Research indicates that some supplements can cause adverse effects and interact with medications. Therefore, to ensure safe usage, it is imperative to implement stricter regulations, enhance reporting systems, and boost consumer awareness.

Indexed as

Dietary SupplementsCOVID-19Gastrointestinal DiseasesHumansSARS-CoV-2

Identifiers

PMID39681616

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.